Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.

BJU international - 1 May 2007

Figg William D, Li Haiqing, Sissung Tristan, Retter Avi, Wu Shenhong, Gulley James L, Arlen Phil, Wright John J, Parnes Howard, Fedenko Kathy, Latham Lea, Steinberg Seth M, Jones Elizabeth, Chen Clara, Dahut William

Abstract excerpt

OBJECTIVE: To evaluate the combination of docetaxel plus estramustine (which prolongs survival in patients with androgen-independent prostate cancer, AIPC), and thalidomide (that also adds to docetaxel activity), both pre-clinically and clinically in AIPC. PATIENTS, MATERIALS AND METHODS: In the pre-clinical evaluation we injected PC3 cells subcutaneously into severely combined immunodeficient mice and started...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1B1

Share to Cytochrome P-450 Enzyme System

Share to Docetaxel

Share to Mice, Nude

Share to Taxoids

Share to Thalidomide

Source

Identifiers

PMID: 17437439
DOI: 10.1111/j.1464-410X.2007.06763.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.PMID 17437439Read ↗

A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.Semantic proximity Read ↗

A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.Semantic proximity Read ↗

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.Semantic proximity Read ↗

Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisSemantic proximity Read ↗

Orchiectomy as an alternative to injectable therapies as a tool to improve access to new generation systemic treatments for Advanced Prostate Cancer in Developing CountriesSemantic proximity Read ↗

Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.Semantic proximity Read ↗

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.Semantic proximity Read ↗

Recent trends in the management of advanced prostate cancerSemantic proximity Read ↗

Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer CellsSemantic proximity Read ↗

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.Semantic proximity Read ↗

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.Semantic proximity Read ↗

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.